
Home » Kareus initiates phase I trial in Alzheimer's disease
Kareus initiates phase I trial in Alzheimer's disease
January 4, 2013
Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
The Phase I clinical trial is a randomized, double-blind, placebo-controlled two-part study to assess the safety, tolerability and pharmacokinetics of single ascending oral doses and of multiple ascending oral doses of KU-046 in 54 healthy young volunteers. The study is being conducted by Quintiles in the U.S.
"We are excited to have obtained IND approval that will bring KU-046 into clinical development,” said Patrick Doyle, chief business and corporate development, Kareus Therapeutics. “This is a positive milestone, demonstrating the power of Kareus' innovation platform, which has already shown significant improvement in cognition in a number of pre-clinical models. We now believe we are well positioned to partner KU-046 to take it into the next stages of its development."
KU-046 targets bioenergetics pathways upstream from the increased abeta peptide production found in Alzheimer's disease. It has demonstrated significant improvement in cognition in a number of pre-clinical models.
Dr. Uday Saxena, chief R&D, Kareus Therapeutics, added, "The successful discovery of KU-046 has prompted us to use our bioenergetics and KARLECT platforms to discover drug candidates for other CNS diseases such as Parkinson's and Huntington's disease which have similar energy dysfunction."
Upcoming Events
-
25Apr
-
26Apr
-
27Apr
-
17May
-
21May